MX336355B - Formulacion resistente al abuso. - Google Patents

Formulacion resistente al abuso.

Info

Publication number
MX336355B
MX336355B MX2011009214A MX2011009214A MX336355B MX 336355 B MX336355 B MX 336355B MX 2011009214 A MX2011009214 A MX 2011009214A MX 2011009214 A MX2011009214 A MX 2011009214A MX 336355 B MX336355 B MX 336355B
Authority
MX
Mexico
Prior art keywords
pores
abuse resistant
resistant formulation
network
abuse
Prior art date
Application number
MX2011009214A
Other languages
English (en)
Other versions
MX2011009214A (es
Inventor
Susanne Bredenberg
Anna Dahlgren
Anders Sägström
Hakan Engqvist
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of MX2011009214A publication Critical patent/MX2011009214A/es
Publication of MX336355B publication Critical patent/MX336355B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se provee una composición farmacéutica de liberación sostenida que comprende una red continua sólida que comprende un excipiente con una alta resistencia mecánica, dicha red también comprende poros dentro de los cuales está esparcida una mezcla de un ingrediente activo y un agente formador de película, en donde dichos poros se forman durante la producción de la composición; las composiciones de la invención son particularmente útiles como formulaciones resistentes al abuso que comprenden analgésicos opioides que se pueden usar en el tratamiento del dolor crónico.
MX2011009214A 2009-03-04 2010-03-02 Formulacion resistente al abuso. MX336355B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2009000592 2009-03-04
PCT/GB2010/000374 WO2010100414A1 (en) 2009-03-04 2010-03-02 Abuse resistant formulation

Publications (2)

Publication Number Publication Date
MX2011009214A MX2011009214A (es) 2011-09-28
MX336355B true MX336355B (es) 2016-01-14

Family

ID=40823586

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009214A MX336355B (es) 2009-03-04 2010-03-02 Formulacion resistente al abuso.

Country Status (17)

Country Link
US (2) US9622972B2 (es)
EP (1) EP2403482B1 (es)
JP (1) JP5728705B2 (es)
KR (1) KR101751906B1 (es)
CN (1) CN102341096B (es)
AU (1) AU2010219449B2 (es)
BR (1) BRPI1009121A2 (es)
CA (1) CA2753664C (es)
DK (1) DK2403482T3 (es)
EA (1) EA031154B1 (es)
ES (1) ES2660674T3 (es)
IL (1) IL214583A (es)
MX (1) MX336355B (es)
NO (1) NO2403482T3 (es)
NZ (1) NZ594513A (es)
PL (1) PL2403482T3 (es)
WO (1) WO2010100414A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
ES2712989T3 (es) 2009-10-30 2019-05-17 Ix Biopharma Ltd Forma de dosificación sólida de disolución rápida
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
ES2691982T3 (es) * 2012-11-30 2018-11-29 Acura Pharmaceuticals, Inc. Liberación autorregulada de un principio activo farmacéutico
US10420729B2 (en) * 2013-03-15 2019-09-24 R.P. Scherer Technologies, Llc Abuse resistant capsule
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
GB201502073D0 (en) 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
US10398343B2 (en) 2015-03-02 2019-09-03 Mc10, Inc. Perspiration sensor
EP3210596A1 (en) * 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical composition
RU2743446C2 (ru) 2016-02-29 2021-02-18 Эмпликъюре Аб Устройства для испарения и ингаляции активно действующих веществ
CN105997907A (zh) * 2016-05-16 2016-10-12 胡小丽 高血压治疗药丸
CN105769798A (zh) * 2016-05-16 2016-07-20 张阳 一种高血压治疗药物的制备方法
CN105997915A (zh) * 2016-05-16 2016-10-12 张阳 一种高血压治疗用缓释片剂
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
GB201714412D0 (en) * 2017-09-07 2017-10-25 Emplicure Ab Evaporation devices containing plant material
CN108720990A (zh) * 2018-06-04 2018-11-02 界首市龙鑫生物科技有限公司 一种能够加快伤口愈合的医用冷敷贴
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US20250228771A1 (en) * 2022-04-01 2025-07-17 EMPLICURE AB (publ) Alkaline intraoral products

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE93384T1 (de) 1983-11-14 1993-09-15 Univ Kentucky Res Found Poroese mikrokugeln zur arzneistoffabgabe sowie verfahren zu deren herstellung.
GB2196252B (en) * 1986-09-18 1990-10-17 London Pharmacy Innovation Gastric controlled-release dosage forms
IT1197316B (it) 1986-10-01 1988-11-30 Proter Spa Formulazione galenica ad uso orale di derivati della reina a lento rilascio per impiego terapeutico
JP2702953B2 (ja) 1988-01-30 1998-01-26 オリンパス光学工業株式会社 薬液含浸セラミックス
IT1216570B (it) 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
JPH0230988A (ja) 1988-07-20 1990-02-01 Toshiba Corp 宇宙軌道上発電プラント
JPH02268104A (ja) 1989-04-07 1990-11-01 Kanebo Ltd 抗菌性組成物
US5443812A (en) 1989-04-24 1995-08-22 Kanebo Ltd. Stabilized synthetic zeolite and a process for the preparation thereof
JPH07188000A (ja) 1993-12-27 1995-07-25 Bridgestone Corp 薬用被覆材
JPH0930988A (ja) 1995-07-21 1997-02-04 Sumitomo Osaka Cement Co Ltd 薬剤徐放性多孔質セラミックス成形体及びその製造方法
GB2307862A (en) 1995-12-05 1997-06-11 David Jehan Patch structures for transdermal therapy
US6777001B1 (en) 1996-11-25 2004-08-17 Kabushiki Kaisya Advance Method of production of ceramics
US5902591A (en) 1997-04-03 1999-05-11 La Prairie Sa Stable topical cosmetic/pharmaceutical emulsion compositions containing ascorbic acid
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6123925A (en) 1998-07-27 2000-09-26 Healthshield Technologies L.L.C. Antibiotic toothpaste
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
AUPQ573300A0 (en) 2000-02-21 2000-03-16 Australian Nuclear Science & Technology Organisation Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
WO2001072663A2 (en) 2000-03-24 2001-10-04 Lyles Mark B High density porous materials
DE60128683T2 (de) 2000-04-11 2008-01-24 Sankyo Co., Ltd. Stabilisierte pharmazeutische zusammenstellungen die den calziumkanalblocker azelnidipine enthalten
US20020122828A1 (en) 2001-03-02 2002-09-05 Jun Liu Hybrid porous materials for controlled release
DE60226012T2 (de) * 2001-03-05 2009-05-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Geschmacksmaskierte pharmazeutische formulierungen
DE60238422D1 (de) 2001-09-24 2011-01-05 Boston Scient Ltd Optimierte dosierung bei paclitaxelhaltigen stents
CN100478026C (zh) 2001-09-28 2009-04-15 纽特休迪克斯公司 用于生物学组分的传递系统
EP1448231A1 (en) 2001-11-19 2004-08-25 Control Delivery Systems, Inc. Topical delivery of codrugs
WO2003090729A1 (en) 2002-04-23 2003-11-06 Alza Corporation Transdermal analgesic systems with reduced abuse potential
WO2003092785A1 (en) 2002-04-30 2003-11-13 Morteza Shirkhanzadeh Arrays of microneedles comprising porous calcium phosphate coating and bioactive agents
US8062573B2 (en) 2002-09-16 2011-11-22 Theraject, Inc. Solid micro-perforators and methods of use
SE524334C2 (sv) 2002-09-30 2004-07-27 Cerbio Tech Ab Värmegenererande biokompatibla keramiska material och förfarande för dess framställning
SE525236C2 (sv) 2002-10-31 2005-01-11 Cerbio Tech Ab Förfarande för framställning av strukturerade keramiska beläggningar och belagda anordningar framställda med detta förfarande
SE524494C2 (sv) 2002-12-31 2004-08-17 Doxa Ab Kemiskt bundna biomaterialelement med skräddarsydda egenskaper
US20070258926A1 (en) 2003-10-15 2007-11-08 Ltt Bio-Pharma Co., Ltd. Composition containing retinoic acid nanoparticles coated with inorganic salt of polyvalent metal
KR20060115398A (ko) 2003-10-29 2006-11-08 독사 악티에볼락 개선된 생체 재료의 초기 및 최종 특성을 위한 2단계시스템
US20050181049A1 (en) 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
CA2548915C (en) 2003-12-31 2012-10-16 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
WO2005075016A1 (ja) 2004-02-03 2005-08-18 Hisamitsu Pharmaceutical Co., Inc. 経皮薬物投与装置用インタフェース
US7315758B2 (en) 2004-06-03 2008-01-01 Lynntech, Inc. Transdermal delivery of therapeutic agent
US20060016578A1 (en) * 2004-06-24 2006-01-26 Shine Ying Co., Ltd. [high-performance two-phase flow evaporator]
AU2005256322C1 (en) 2004-06-28 2011-07-07 Veloxis Pharmaceuticals, Inc. Porous tablets as carriers for liquid formulations
AU2005271781A1 (en) 2004-07-13 2006-02-16 Altairnano, Inc. Ceramic structures for prevention of drug diversion
JP2008506700A (ja) * 2004-07-13 2008-03-06 アルテアーナノ，インコーポレーテッド 薬物の制御された放出のためのセラミック構造体
US7537590B2 (en) 2004-07-30 2009-05-26 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
KR20070043894A (ko) 2004-08-19 2007-04-25 알자 코포레이션 제어 방출형 나노입자 활성제 제제 제형 및 방법
US8535702B2 (en) 2005-02-01 2013-09-17 Boston Scientific Scimed, Inc. Medical devices having porous polymeric regions for controlled drug delivery and regulated biocompatibility
FR2881652B1 (fr) 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
WO2006096544A1 (en) 2005-03-04 2006-09-14 Altairnano, Inc. Ceramic structures for controlled release of biologically active substances
DE102005040429A1 (de) 2005-08-25 2007-03-01 Heraeus Kulzer Gmbh Wirkstofffreisetzungssystem und seine Verwendung
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
US7682445B2 (en) 2005-12-08 2010-03-23 Doxa Ab Powdered CBC system with improved reaction feature
US20090104286A1 (en) 2005-12-29 2009-04-23 Robert Basic Regulation of allergic reaction
US20070212414A1 (en) 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20070248656A1 (en) 2006-04-25 2007-10-25 Galer Bradley S Topical preparation dispensers and methods of using the same
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
DE102006028781A1 (de) 2006-06-23 2007-12-27 Robert Bosch Gmbh Verfahren zur Herstellung von porösen Mikronadeln und ihre Verwendung
US20080214987A1 (en) 2006-12-22 2008-09-04 Nanomed Devices, Inc. Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances
WO2008105739A1 (en) 2007-03-01 2008-09-04 Doxa Ab Drug implant carrier for drug delivery
EP2131878A4 (en) 2007-03-01 2012-12-26 Doxa Ab INJECTABLE CEMENT COMPOSITION FOR ORTHOPEDIC AND DENTAL PURPOSES
WO2008105737A1 (en) 2007-03-01 2008-09-04 Doxa Ab Stable cement composition for orthopaedic and dental use
EP2139531A4 (en) 2007-03-28 2013-01-09 Doxa Ab CARRIER FOR DRUG DISPENSING
CN101104080B (zh) 2007-04-24 2011-06-22 深圳市鸿华投资有限公司 沸石止血敷料及其制备方法和用途
GB0709541D0 (en) * 2007-05-17 2007-06-27 Jagotec Ag Pharmaceutical excipient
EP2100850A1 (en) 2008-03-11 2009-09-16 Stichting Voor De Technische Wetenschappen Microneedle array and a method for manufacturing microneedles
WO2010096704A2 (en) 2009-02-19 2010-08-26 Alex Garfield Bonner Porous interpenetrating polymer network

Also Published As

Publication number Publication date
CN102341096B (zh) 2015-02-18
AU2010219449A1 (en) 2011-09-01
US20120015007A1 (en) 2012-01-19
EA201101281A1 (ru) 2012-02-28
WO2010100414A1 (en) 2010-09-10
US10543203B2 (en) 2020-01-28
ES2660674T3 (es) 2018-03-23
MX2011009214A (es) 2011-09-28
KR101751906B1 (ko) 2017-06-29
IL214583A (en) 2016-04-21
EP2403482B1 (en) 2017-12-27
US9622972B2 (en) 2017-04-18
CA2753664A1 (en) 2010-09-10
CA2753664C (en) 2019-11-05
AU2010219449B2 (en) 2014-12-18
CN102341096A (zh) 2012-02-01
KR20110122838A (ko) 2011-11-11
JP5728705B2 (ja) 2015-06-03
JP2012519675A (ja) 2012-08-30
DK2403482T3 (en) 2018-03-05
EA031154B1 (ru) 2018-11-30
IL214583A0 (en) 2011-09-27
EP2403482A1 (en) 2012-01-11
PL2403482T3 (pl) 2018-06-29
BRPI1009121A2 (pt) 2018-06-19
US20170239229A1 (en) 2017-08-24
NO2403482T3 (es) 2018-05-26
NZ594513A (en) 2013-10-25

Similar Documents

Publication Publication Date Title
MX2011009214A (es) Formulacion resistente al abuso.
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
WO2012032209A3 (es) Uso de un agonista de trpm8 para la elaboración de un medicamento para el tratamiento de xeroftalmia, sequedad vaginal y síndrome de la boca seca y uso de un antagonista de trpm8 para la elaboración de un medicamento pra el tratamiento de la epífora.
MX2011013201A (es) Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MX356111B (es) Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.
MX2014011815A (es) Composiciones farmaceuticas de liberacion inmediata con propiedades disuasivas de abuso.
HK1200741A1 (en) Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
NZ704011A (en) Abuse deterrent pharmaceutical compositions for controlled release
IL234166B (en) Isoindoline compounds, a pharmaceutical composition containing it and its use in the preparation of a medicine
WO2009091576A3 (en) Parenteral formulations of dopamine agonists
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
SG195375A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
MX362838B (es) Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
TN2015000244A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MX359288B (es) Forma iv del clorhidrato de ivabradina.
IL198657A0 (en) Use of compositions comprising capsaicinoid compunds in the preparation of medicaments and as medicaments for the treatment of keratoconjunctivitis sicca
TN2011000651A1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application
WO2012053013A3 (en) Pharmaceutical compositions of anti-acne agents
IL213671A (en) Pharmaceutical preparations containing alglitazar, a process for their preparation and use for the preparation of medicines
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
EP2682129A3 (en) Compositions Comprising Muscarinic Receptor Antagonist and Glucose Anhydrous
WO2010098625A2 (ko) 약제학적 제제